Leflunomide in solid organ transplantation and polyoma virus infection

Advances in Experimental Medicine and Biology

Volumn 577, Issue , 2006, Pages 255-265

  Josephson, Michelle A ^a   Javaid, Basit ^a   Kadambi, Pradeep V ^a   Meehan, Shane M ^a   Williams, James W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE;

HUMAN; IMMUNOLOGY; ORGAN TRANSPLANTATION; PATHOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; VIRUS INFECTION;

ANTIVIRAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; ORGAN TRANSPLANTATION; PAPILLOMAVIRUS INFECTIONS; POSTOPERATIVE COMPLICATIONS;

EID: 33745605569     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-32957-9_18     Document Type: Review

References (66)

1. Chong AS, Huang W, Liu W et al. In vivo activity of leflunomide: Pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999; 68:100-109.
2. Kuchle CC, Thoenes GH, Langer KH et al. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23:1083-1086.
3. Lin Y, Waer M. In vivo mechanism of action of leflunomide: Selective inhibition of the capacity of B lymphocytes to make T-independent xenoantibodies. Transplant Proc 1996; 28:3085.
4. Lin Y, Goebels J, Xia G et al. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. Nat Med 1998; 4:173-180.
5. Williams JW, Xiao F, Foster P et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production. Reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57:1223-1231.
6. Xiao F, Chong A, Shen J et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995; 60:1065-1072.
7. Xiao F, Shen J, Chong A et al. Control and reversal of chronic xenograft rejection in hamster-to-rat cardiac transplantation. Transplant Proc 1996; 28:691-692.
8. Knight DA, Hejmanowski AQ, Dierksheide JE et al. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 71:170-174.
9. Waldman WJ, Knight DA, Lurain NS et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68:814-825.
10. Waldman WJ, Knight DA, Blinder L et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999; 42:412-418.
11. Sponsor: Hoechst Marion Roussel. Summary of Nda 20-905. Clinical Pharmacology/Biopharmaceutics Review 1998; 31-33.
12. Williams JW, Mital D, Chong A et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73:358-366.
13. Elder RT, Xu X, Williams JW et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159:22-27.
14. Ghosh S, Zheng Y, Jun X et al. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4- (Trifluoromethoxy)phenyl] propenamide: An inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin Cancer Res 1998; 4:2657-2668.
15. Mahajan S, Ghosh S, Sudbeck EA et al. Rational design and synthesis of a novel anti-leukemic agent targeting bruton's tyrosine kinase (Btk), Lfm-A13 [Alpha-Cyano-Beta-Hydroxy-Beta-Methyl-N-(2, 5-Dibromophenyl)propenamide]. J Biol Chem 1999; 274:9587-9599.
16. Mattar T, Kochhar K, Bartlett R et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. Febs Lett 1993; 334:161-164.
17. Shawver LK, Schwartz DP, Mann E et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(Trifluoromethyl)-Phenyl]5-Methylisoxazole-4-Carboxamide. Clin Cancer Res 1997; 3:1167-1177.
18. Siemasko K, Chong AS, Jack HM et al. Inhibition of Jak3 and Stat6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in Igg1 production. J Immunol 1998; 160:1581-1588.
19. Xu X, Williams JW, Bremer EG et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270:12398-12403.
20. Xu X, Blinder L, Shen J et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in Mrl/Mpj-Lpr/Lpr mice. J Immunol 1997; 159:167-174.
21. Xu X, Shen J, Mall JW et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action. Biochem Pharmacol 1999; 58:1405-1413.
22. Mcchesney LP, Xiao F, Sankary HN et al. An evaluation of leflunomide in the canine renal transplantation model transplantation 1994; 57:1717-1722.
23. Sankary HN, Yin DP, Chong AS et al. Fk506 treatment in combination with leflunomide in hamster-to-rat heart and liver Xenograft transplantation. Transplantation 1998; 66:832-837.
24. Cherwinski HM, Cohn RG, Cheung P et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275:1043-1049.
25. Davis JP, Cain GA, Pitts WJ et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35:1270-1273.
26. Knecht W, Loffler M. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem Pharmacol 1998; 56:1259-1264.
27. Williamson RA, Yea CM, Robson PA et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270:22467-22472.
28. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks tnf-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162:2095-2102.
29. Cherwinski HM, Byars N, Ballaron SJ et al. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995; 44:317-322.
30. Silva Jr HT, Cao W, Shorthouse RA et al. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Transplant Proc 1997; 29:1292-1293.
31. Allison AC. Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000; 47:63-83.
32. Nair RV, Cao W, Morris RE. Inhibition of smooth muscle cell proliferation in vitro by leflunomide. A new immunosuppressant, is antagonized by uridine Immunol. Lett 1995; 47:171-174.
33. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79:1283-1316.
34. Border WA, Okuda S, Languino LR et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346:371-374.
35. Buchdunger E, Zimmermann J, Mett H et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995; 92:2558-2562.
36. Doi T, Vlassara H, Kirstein M et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Nad Acad Sci USA 1992; 89:2873-2877.
37. Floege J, Eng E, Young BA et al. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 1993; 92:2952-2962.
38. Floege J, Johnson RJ. Multiple roles for platelet-derived growth factor in renal disease. Miner Electrolyte Metab 1995; 21:271-282.
39. Floege J, Ostendorf T, Janssen U et al. Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 1999; 154:169-179.
40. Gilbert RE, Kelly DJ, Mckay T et al. Pdgf signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001; 59:1324-1332.
41. Iida H, Seifert R, Alpers CE et al. Platelet-derived growth factor (Pdgf) and Pdgf receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci USA 1991; 88:6560-6564.
42. Isaka Y, Fujiwara Y, Ueda N et al. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92:2597-2601.
43. Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2:418-423.
44. Johnson RJ, Raines EW, Floege J et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992; 175:1413-1416.
45. Ostendorf T, Kunter U, Grone HJ et al. Specific antagonism of Pdgf prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001; 12:909-918.
46. Ostendorf T, Kunter U, Van Roeyen C et al. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 2002; 13:658-667.
47. Tang WW, Ulich TR, Lacey DI et al. Platelet-derived growth factor-bb induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 1996; 148:1169-1180.
48. Throckmorton DC, Brogden AP, Min B et al. Pdgf and Tgf-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995; 48:111-117.
49. Yagi M, Kato S, Kobayashi Y et al. Beneficial effects of a novel inhibitor of platelet-derived growth factor Receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis. Gen Pharmacol 1998; 31:765-773.
50. Dimitrijevic M, Bartlett RR. Leflunomide, A novel immunomodulating drug. Inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc 1996; 28:3086-3087.
51. Kraan MC, De Koster BM, Elferink JG et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: Findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43:1488-1495.
52. Miljkovic D, Samardzic T, Drakulic D et al. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast I1-6 production by distinct mechanisms. Cytokine 2002; 19:181-186.
53. Siemasko KF, Chong AS, Williams JW et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61:635-642.
54. Mizushima Y, Amano Y, Kitagawa H et al. Oral administration of leflunomide (Hwa486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. J Pharmacol Exp Ther 1999; 288:849-857.
55. Burger D, Begue-Pastor N, Benavent S et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003; 42:89-96.
56. Pinschewer DD, Ochsenbein AF, Fehr T et al. Leflunomide-mediated suppression of antiviral antibody and T cell responses: Differential restoration by uridine. Transplantation 2001; 72:712-719.
57. Waldman WJ, Bickerstaff A, Gordillo G et al. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 72:1578-1582.
58. Swan SK, Crary GS, Guijarro C et al. Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. Transplantation 1995; 60:887-890.
59. Xiao F, Chong A, Shen J et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995; 60:1065-72.
60. Kemp E, Dieperink H, Jensen J et al. Newer immunosuppressive drugs in concordant Xenografting-transplantation of hamster heart to rat. Xenotransplantation 1994; 1:102-108.
61. Savikko J, Von Willebrand E, Hayry P. Leflunomide analogue Fk778 is vasculoprotective independent of its immunosuppressive effect: Potential applications for restenosis and chronic rejection. Transplantation 2003; 76:455-458.
62. Hardinger KL, Wang CD, Schnitzler MA et al. Prospective, Pilot, Open-label, Short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2002; 2:867-871.
63. Avery RK, Bolwell BJ, Yen-Lieberman B et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004.
64. John GT, Manivannan J, Chandy S et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004; 77:1460-1461.
65. Josephson MA, Kadambi PV, Javaid B et al. The use of Leflunomide in vitally infected transplant patients. J Am Soc Nephrol 2004; 15:523a.
66. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-723.